ALGS FY 2023 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+11.7% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$88M-567.5% margin

Net Income

-$88M-564.6% margin

EPS (Diluted)

$-3.52

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$79M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$152M

Total Liabilities

$59M

Stockholders' Equity

$92M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$14M	+11.7%
Gross Profit	$16M	$14M	+11.7%
Operating Income	-$88M	-$98M	+9.7%
Net Income	-$88M	-$96M	+8.7%